CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Hence, pyrvinium alone and its combination with dasatinib preferentially target BP-CML compared to cord blood CD34+ progenitors by inhibiting their proliferation and self-renewal capacity.